ArticleClinical and translational science2025

Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell-Derived Cardiomyocytes and FDA Adverse Events Reporting System.

Shota Yanagida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.